Timolol Eye Drops in the Treatment of Acute Migraine Headache

Migraine Clinical Trial

Official title:

Timolol Eye Drops in the Treatment of Acute Migraine Headache

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02630719
• Other study ID #: 15-152
• Secondary ID: #15-060
• Status: Terminated
• Phase: N/A
• Start date: January 2016
• Est. completion date: August 1, 2017

Study information

• Verified date: April 2019
• Source: University of Missouri, Kansas City
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: August 1, 2017
• Est. primary completion date: August 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of migraine headache

Exclusion Criteria

• Non-migraine headache

• Use of systemic beta-blocker

• Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease

• Medical history of difficulty breathing, asthma or chronic obstructive pulmonary disease or other pulmonary disease

• Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis, current use of other ophthalmic medications

• Previous adverse reaction to timolol or other beta-blockers

• Inability to self-administer eye drop due to physical or cognitive disorders

• Currently pregnant or breastfeeding

• Pregnant in the past year

• Non-english speaker

Related Conditions & MeSH terms

• Headache
• Migraine
• Migraine Disorders

Intervention

Drug:
• Timolol eye drops
eye drops
• Artificial tears
Placebo drop

Locations

Country	Name	City	State
United States	Truman Medical Center	Kansas City	Missouri

Sponsors (2)

Lead Sponsor	Collaborator
University of Missouri, Kansas City	Truman Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Timolol Eye Drops in the Treatment of Acute Migraine Headache	Percent of migraine attacks at 0 or 1 on the 4-point Rating Scale recommended by the International Headache Society: 0: no headache; mild headache; moderate headaches; severe headache	4 months